Latest news with #NeoGenomics
Yahoo
11-07-2025
- Business
- Yahoo
NeoGenomics, RadNet, Pediatrix Medical Group, Penumbra, and Neogen Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada. The wider market sentiment turned negative after the White House announced plans to impose a 35% tariff on Canadian imports, sparking renewed fears of a trade war. This news prompted a sell-off across major U.S. indexes, including the S&P 500 and the Dow Jones Industrial Average, as investors grew concerned about the potential economic impact of escalating protectionist policies. The healthcare sector is especially vulnerable to such tensions due to its deeply integrated supply chains with Canada for pharmaceuticals and medical devices, meaning increased costs and potential disruptions. Additionally, ongoing U.S. policy headwinds aimed at lowering drug prices and specific corporate challenges, like those faced by UnitedHealth Group, further compounded the sector's decline. As a result, the Health Care SPDR ETF (XLV) fell 1.0%, underperforming even as major indices pared some losses. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Testing & Diagnostics Services company NeoGenomics (NASDAQ:NEO) fell 3.5%. Is now the time to buy NeoGenomics? Access our full analysis report here, it's free. Testing & Diagnostics Services company RadNet (NASDAQ:RDNT) fell 3.3%. Is now the time to buy RadNet? Access our full analysis report here, it's free. Specialized Medical & Nursing Services company Pediatrix Medical Group (NYSE:MD) fell 3.2%. Is now the time to buy Pediatrix Medical Group? Access our full analysis report here, it's free. Medical Devices & Supplies - Cardiology, Neurology, Vascular company Penumbra (NYSE:PEN) fell 3%. Is now the time to buy Penumbra? Access our full analysis report here, it's free. Medical Devices & Supplies - Diversified company Neogen (NASDAQ:NEOG) fell 3.1%. Is now the time to buy Neogen? Access our full analysis report here, it's free. NeoGenomics's shares are extremely volatile and have had 34 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. NeoGenomics is down 56.1% since the beginning of the year, and at $7.25 per share, it is trading 61.1% below its 52-week high of $18.61 from January 2025. Investors who bought $1,000 worth of NeoGenomics's shares 5 years ago would now be looking at an investment worth $207.09. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
Yahoo
05-07-2025
- Business
- Yahoo
The past five years for NeoGenomics (NASDAQ:NEO) investors has not been profitable
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We don't wish catastrophic capital loss on anyone. For example, we sympathize with anyone who was caught holding NeoGenomics, Inc. (NASDAQ:NEO) during the five years that saw its share price drop a whopping 79%. And we doubt long term believers are the only worried holders, since the stock price has declined 44% over the last twelve months. Shareholders have had an even rougher run lately, with the share price down 14% in the last 90 days. Since shareholders are down over the longer term, lets look at the underlying fundamentals over the that time and see if they've been consistent with returns. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. Given that NeoGenomics didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Shareholders of unprofitable companies usually desire strong revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth. Over five years, NeoGenomics grew its revenue at 9.9% per year. That's a fairly respectable growth rate. So the stock price fall of 12% per year seems pretty steep. The truth is that the growth might be below expectations, and investors are probably worried about the continual losses. You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values). It's good to see that there was some significant insider buying in the last three months. That's a positive. That said, we think earnings and revenue growth trends are even more important factors to consider. You can see what analysts are predicting for NeoGenomics in this interactive graph of future profit estimates. Investors in NeoGenomics had a tough year, with a total loss of 44%, against a market gain of about 15%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 12% over the last half decade. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. For instance, we've identified 2 warning signs for NeoGenomics that you should be aware of. There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. — Investing narratives with Fair Values Suncorp's Next Chapter: Insurance-Only and Ready to Grow By Robbo – Community Contributor Fair Value Estimated: A$22.83 · 0.1% Overvalued Thyssenkrupp Nucera Will Achieve Double-Digit Profits by 2030 Boosted by Hydrogen Growth By Chris1 – Community Contributor Fair Value Estimated: €14.40 · 0.3% Overvalued Tesla's Nvidia Moment – The AI & Robotics Inflection Point By BlackGoat – Community Contributor Fair Value Estimated: $359.72 · 0.1% Overvalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
02-07-2025
- Business
- Yahoo
Here's Why NeoGenomics (NEO) Sold Off in Q1
Janus Henderson Investors, an investment management company, released its 'Janus Henderson Venture Fund' first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned -8.61% in the first quarter, compared to the Russell 2000 Growth Index's -11.12% return. Stock selection in the consumer discretionary sector contributed to the fund's relative performance in the quarter, while selection in healthcare detracted. Stocks declined in the quarter as the uncertainty over tariffs and other Trump administration policies dampened the optimism that had driven momentum in the fourth quarter of 2024. In addition, please check the fund's top five holdings to know its best picks in 2025. In its first-quarter 2025 investor letter, Janus Henderson Venture Fund highlighted stocks such as NeoGenomics, Inc. (NASDAQ:NEO). Headquartered in Fort Myers, Florida, NeoGenomics, Inc. (NASDAQ:NEO) is a network of clinical laboratories that focuses on cancer testing. The one-month return of NeoGenomics, Inc. (NASDAQ:NEO) was 0.41%, and its shares lost 46.03% of their value over the last 52 weeks. On July 1, 2025, NeoGenomics, Inc. (NASDAQ:NEO) stock closed at $7.41 per share, with a market capitalization of $953.63 million. Janus Henderson Venture Fund stated the following regarding NeoGenomics, Inc. (NASDAQ:NEO) in its Q1 2025 investor letter: "NeoGenomics, Inc. (NASDAQ:NEO) was a detractor in the healthcare sector. NeoGenomics provides diagnostic tests that help doctors and researchers target oncology treatments by isolating genetic markers that may distinguish different kinds of cancers. While the company continued to deliver double-digit top-line growth, the stock sold off on concerns over the planned departure of its well-regarded chief executive officer. However, the company has articulated an orderly succession plan, and we remain constructive on its execution and pursuit of higher margins." An oncologist in a hospital laboratory discussing the results of a clinical service test. NeoGenomics, Inc. (NASDAQ:NEO) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 17 hedge fund portfolios held NeoGenomics, Inc. (NASDAQ:NEO) at the end of the first quarter, which was 14 in the previous quarter. NeoGenomics, Inc. (NASDAQ:NEO) reported revenue of $168 million in the first quarter 2025, an increase of 8% over prior year. While we acknowledge the potential of NeoGenomics, Inc. (NASDAQ:NEO) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. While we acknowledge the potential of NEO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
01-07-2025
- Business
- Yahoo
NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025
FORT MYERS, Fla., July 01, 2025--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its second quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, July 29, 2025. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at or by clicking here. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domestic) or (973) 528-0011 (international) at least five minutes prior to the call. The participant access code is 859170. About NeoGenomics, Inc. NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom. View source version on Contacts Investor Contact Kendra Websterir@ Media Contact Andrea Sampsonasampson@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
01-07-2025
- Business
- Business Wire
NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025
FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its second quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, July 29, 2025. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at or by clicking here. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domestic) or (973) 528-0011 (international) at least five minutes prior to the call. The participant access code is 859170. About NeoGenomics, Inc. NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom.
